Simulated incidence of DMR and survival after TKI switch according to the model assumption. Simulated cumulative incidence of MR4.5 and MR4.0 in the present model in imatinib first (A), dasatinib first (B), and nilotinib first (C), in comparison with the results of the DASISION trial and ENENTnd trial. Simulated overall survival (OS) under second-line treatment with imatinib after intolerance to dasatinib or nilotinib (D), dasatinib after resistance or intolerance to imatinib or nilotinib (E), or nilotinib after resistance or intolerance to imatinib or dasatinib (F), in comparison with the results of the IRIS trial, the CA180-134 trial, and the CAMN107A2101 trial.